Results 111 to 120 of about 21,696 (215)

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Multilingual Digital Search Behavior Reveals Cultural Disparities in Vitiligo Information Needs in Germany

International Journal of Dermatology, EarlyView.
Multilingual vitiligo‐related Google search queries in Germany (October 2019–May 2023) were extracted and thematically coded across German, English, Turkish, Arabic, Russian, and Polish. Relative patterns highlighted language‐specific emphases in treatment information, camouflage, depigmentation, psychosocial burden, and faith/home‐remedy terms ...
Lilian Rauch, Christine Gasteiger, Markus Böhm, Georg Pliszewski, Tilo Biedermann, Alexander Zink   +5 more
wiley   +1 more source

NFкB pathway suppression as a key driver of pacritinib response in high‐risk myelofibrosis

British Journal of Haematology, EarlyView.
R. Van Dijck, M. ter Borg, B. van der Holt, A. E. C. Broers, M. D. Hazenberg, J. J. Cornelissen, N. P. M. Schaap, E. de Pater, P. A. W. te Boekhorst   +8 more
wiley   +1 more source

Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell–Dendritic Cell Interaction

Immunology, EarlyView.
During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu, Jan Gärtig, Stephan Eiber, Stefan Moder, Raffael Thaler, Matthias Thaler, Juliane Gruen, Marlies Vornhülz, Kevin Bahner, Luana Messa, Benjamin Kühnemuth, Jennifer Müller, Konstantin Schnell, Antonia Beimert, Carolin Perleberg, Natascha Röhrle, Maximilian Martin Ludwig Knott, Linda Hammann, Vanessa Wittmann, Patrick Layritz, Moritz Rapp, Carole Bourquin, Julia Mayerle, Stefan Endres, David Anz   +24 more
wiley   +1 more source

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study

Annals of Hematology
Chronic graft-versus-host disease (cGVHD) is a major complication for long-term survivors after hematopoietic cell transplantation (HCT). Bronchiolitis obliterans syndrome (BOS) is the crucial manifestation of lung cGVHD. Ruxolitinib has been approved by
Yuqing Tu, Lingyi Yang, Yaxin Cheng, Yanming Zhang, Yinghao Lu, Shushu Xu, Xiaoli Li, Mimi Xu, Mengqi Xiang, Yi Fan, Yuhua Ru, Yang Xu, Feng Chen, Xiaojin Wu, Yulian Zheng, Fei Li, Yue Han, Xiaowen Tang, Huiying Qiu, Miao Miao, Ye Zhao, Xiaoyu Zhu, Depei Wu, Jia Chen   +23 more
doaj   +1 more source

Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3

Blood Advances
: Azole antifungal agents, commonly used for preventing invasive fungal infections in graft-versus-host disease (GVHD), are known to affect ruxolitinib metabolism.
Zahra Mahmoudjafari, Emily Kintsch, Zhenyi Xue, Valkal Bhatt, John Galvin, Franco Locatelli, Robert Zeiser   +6 more
doaj   +1 more source

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa, Vimal H. Prajapati, H. Chih‐ho Hong, Viktoria Eleftheriadou, Athanasios Tsianakas, Alexander A. Navarini, Ketty Peris, Eingun James Song, Raj Chovatiya, Sébastien Barbarot, Konstantin Popovic, Haq Nawaz, Qian Li, Vivek Purohit, Andreas Wollenberg   +14 more
wiley   +1 more source

Practical management of patients with myelofibrosis receiving ruxolitinib.

, 2013
Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly.
Verstovsek, S, Ross, D, Mesa, R, Keohane, C, Mead, A, Harrison, C, Gotlib, J   +6 more
core   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

European Journal of Haematology, Volume 117, Issue 5, Page 1265-1274, November 2026.
In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernandez‐Boluda, Kazuya Shimoda, Shiyuan Zhang, Catherine Ellis, Jessica Lim, Jasmine Sahni, Vikas Gupta   +11 more
wiley   +1 more source